Ganciclovir

CAS 82410-32-0 5 current records 2 historicalSmall Molecule

Who holds supplier records for Ganciclovir? 5 organisations hold a current record for Ganciclovir: an active US FDA Type II Drug Master File or a CEP. A further 2 organisations have only historical (inactive) DMF filings. 3 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: China (2), Germany (1), India (1) and Italy (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Ganciclovir: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/ganciclovir

Reading the evidence

  • 5 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 4 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (5)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Ganciclovir. Country is the organisation's recorded country, not necessarily the manufacturing site.

  • EXCELLA GMBH AND CO KG
    Active DMF 24337, 15567 · latest filing Nov 2010
    GermanyCEP Company GMP cert on record
  • Shanghai Pharma Group Changzhou Kony Pharmaceutical Co., Ltd.
    Active DMF 28973 · latest filing Apr 2015
    ChinaCEP
  • APITORIA PHARMA PRIVATE LTD
    Active DMF 31402 · latest filing Feb 2017
    India Company GMP cert on record
  • TRIFARMA SPA
    Active DMF 23721 · latest filing Apr 2010
    Italy Company GMP cert on record
  • Zhejiang Charioteer Pharmaceutical Co., Ltd.
    Inactive DMF 27133 · latest filing May 2013
    ChinaCEP Company GMP cert on record
Need Ganciclovir sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (3)

Certificates of Suitability on the EDQM register for Ganciclovir, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

HolderCountryCertificateIssuedEU GMP at holder's address
SHANGHAI PHARMA GROUP CHANGZHOU KONY PHARMACEUTICAL CO., LTD. Luoyang TownCN
CEP 2024-086 - Rev 00
Ganciclovir
Sept 2025—
EXCELLA GMBH & CO. KG FeuchtDE
CEP 2010-257 - Rev 04
Ganciclovir, Anhydrous
Mar 2025Inspected Apr 2026
Germany
Zhejiang Charioteer Pharmaceutical Co., Ltd. XianjuCN
R1-CEP 2013-123 - Rev 01
Ganciclovir
Jun 2019—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (2)

Organisations whose Type II DMFs for Ganciclovir are no longer active. These show a past filing, not current supply.

Show all 2 historical records

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Ganciclovir is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL182).

Chemical identity

IUPAC name
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
Canonical SMILES
C1=NC2=C(N1COC(CO)CO)NC(=NC2=O)N
InChIKey
IRSCQMHQWWYFCW-UHFFFAOYSA-N
Synonyms
BW 759U, BW-759U, Cymevene, Cytovene, Ganciclovir, Gancyclovir, Ganzyk-rtu, NSC-759656, RS-21592, Valganciclovir hydrochloride impurity a, Virgan, Vitrasert

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor; Nucleoside Analog Antiviral
Mechanism of action
DNA Polymerase Inhibitors

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Ganciclovir?

5 organisations hold an active US FDA Type II Drug Master File or a CEP for Ganciclovir: EXCELLA GMBH AND CO KG (Germany), Shanghai Pharma Group Changzhou Kony Pharmaceutical Co., Ltd. (China), APITORIA PHARMA PRIVATE LTD (India), TRIFARMA SPA (Italy) and Zhejiang Charioteer Pharmaceutical Co., Ltd. (China). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Ganciclovir Drug Master Files are active?

EXCELLA GMBH AND CO KG (DMF 24337, 15567), Shanghai Pharma Group Changzhou Kony Pharmaceutical Co., Ltd. (DMF 28973), APITORIA PHARMA PRIVATE LTD (DMF 31402) and TRIFARMA SPA (DMF 23721). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Ganciclovir records mean?

2 organisations have only inactive Type II DMFs for Ganciclovir. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Ganciclovir have a European Certificate of Suitability?

Yes. 3 organisations hold a valid CEP for Ganciclovir on the EDQM register, including SHANGHAI PHARMA GROUP CHANGZHOU KONY PHARMACEUTICAL CO., LTD. Luoyang Town (CN), EXCELLA GMBH & CO. KG Feucht (DE) and Zhejiang Charioteer Pharmaceutical Co., Ltd. Xianju (CN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

How do I qualify a Ganciclovir supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Ganciclovir?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.